<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422019000400041</article-id>
<article-id pub-id-type="doi">10.22201/fm.24484865e.2019.62.4.07</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La próstata: generalidades y patologías más frecuentes]]></article-title>
<article-title xml:lang="en"><![CDATA[The prostate: generalities and most frequent pathologies]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Robles Rodríguez]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garibay Huarte]]></surname>
<given-names><![CDATA[Tania Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta Arreguín]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales López]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Medicina Departamento de Integración de Ciencias Médicas]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Medicina Familiar ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Medicina Departamento de Integración de Ciencias Médicas]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>62</volume>
<numero>4</numero>
<fpage>41</fpage>
<lpage>54</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422019000400041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422019000400041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422019000400041&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La próstata es un órgano fibromuscular y glandular, produce una secreción líquida que forma parte del semen, contiene sustancias que proporcionan nutrientes y un medio adecuado para la supervivencia de los espermatozoides. Su patología es uno de los motivos de consulta más frecuentes en medicina familiar y urología; por ello, es importante reconocer los principales datos clínicos que ayuden a realizar diagnósticos diferenciales entre hiperplasia prostática, cáncer de próstata y prostatitis. La hiperplasia prostática (HP) es la proliferación no maligna de las células epiteliales y del estroma de la glándula prostática, relacionada con el proceso de envejecimiento del hombre. La prevalencia de HP aumenta con la edad, el 50% de los hombres de 51 a 60 años la padece. El mecanismo por el cual la HP puede producir una obstrucción vesical, comprende 2 componentes: uno estático y otro dinámico. Existen síntomas obstructivos e irritativos del tracto urinario inferior que afectan la calidad de vida del paciente, al interferir con sus actividades diarias y patrones de sueño. La anamnesis permite precisar y evaluar la magnitud de estos síntomas, constituyendo así una etapa fundamental del diagnóstico, de ahí la utilidad de utilizar el International Prostate Symptom Score (IPSS). El tacto rectal proporciona datos principales como volumen y consistencia. Los bloqueadores &#945;-adrenérgicos y los inhibidores de la 5&#945;-reductasa son las 2 clases de fármacos utilizados. La prostatitis bacteriana aguda se asocia a infección del aparato urinario inferior. La clasificación de los pacientes con prostatitis depende del estudio bacteriológico de la vía urinaria inferior; los síndromes de prostatitis se pueden clasificar en 5 grupos principales: prostatitis bacteriana aguda, prostatitis bacteriana crónica, síndrome de prostatitis crónica (PC)/síndrome doloroso pélvico crónico (SDPC), prostatitis inflamatoria asintomática y prostatitis granulomatosa. Representa el diagnóstico urológico más frecuente en varones jóvenes. La prevalencia es del 2-16% y representa el 8% de las consultas urológicas. El cáncer de próstata (CP) es el tumor maligno más frecuente en hombres a partir de los 50 años, y su pico máximo es después de los 65 años. Su incidencia ha aumentado en los últimos años debido en parte a la mejora en las técnicas diagnósticas, el aumento de la esperanza de vida y otros factores no tan conocidos como la exposición ambiental, dieta, estilo de vida y genética. La American Cancer Society recomienda la realización de APE con o sin examen digital rectal, comenzando a los 50 años. La American Urology Association recomienda realizarlo a partir de los 40 años y se sugiere realizar biopsia en pacientes con APE igual o superior a 4 ng/mL. La selección del tratamiento depende de la estadificación tumoral y categoría de riesgo, edad del paciente, esperanza de vida, presencia o ausencia de síntomas y efecto de las opciones de tratamiento sobre la calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The prostate is a fibromuscular and glandular organ that produces a liquid secretion that is part of the semen, it contains substances that provide nutrients and an adequate medium for the survival of the sperm. This pathology is one of the most frequent reasons for consultation in family medicine and urology, so it is important to recognize the main clinical data to be able to make differential diagnoses between prostatic hyperplasia, prostate cancer and prostatitis. Prostatic hyperplasia (HP) is the non-malignant proliferation of epithelial cells and the stroma of the prostate gland related to the aging process of men. The prevalence of HP increases with age; 50% of men aged between 51 and 60 have it. The mechanism by which HP can produce a bladder obstruction comprises two components: a static and a dynamic one. There are obstructive and irritative symptoms of the lower urinary tract that affect the quality of life of the patient, interfering with their daily activities and sleep patterns. The anamnesis allows the clinicians to determine and evaluate the magnitude of these symptoms, constituting a fundamental stage of the diagnosis, hence the usefulness of using the IPSS (International Prostate Symptom Score). The rectal examination provides major data such as volume and consistency. &#945;-Adrenergic blockers and 5&#945;-reductase inhibitors are the two types of drugs used. Prostate cancer (PC) is the most frequent malignant tumor in men of 50 years old and its maximum peak is after 65 years. Its incidence has increased in recent years due, in part, to the improvement in diagnostic techniques, the increase in life expectancy and other factors not so well known as environ mental exposure, diet, lifestyle and genetics. The American Cancer Society recommends an APE with or without a digital rectal exam starting at the age 50. The American Urology Association recommends it starting at the age of 40 and a biopsy in patients with PSA equal to or greater than 4 ng / ml is also suggested. The selection of the treatment depends on the tumor staging and category of the risk, the age of the patient, life expectancy, presence or absence of symptoms and the effects of the treatment options on the quality of life. Acute bacterial prostatitis is associated with lower urinary tract infection. The classification of patients with prostatitis depends on the bacteriological study of the lower urinary tract; prostatitis syndromes can be classified into four main groups: acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), asymptomatic inflammatory prostatitis and granulomatous prostatitis. It represents the most frequent urological diagnosis in young males. The prevalence is 2-16% and represents 8% of urological consultations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Próstata]]></kwd>
<kwd lng="es"><![CDATA[hiperplasia]]></kwd>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[prostatitis]]></kwd>
<kwd lng="es"><![CDATA[tacto rectal]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico diferencial]]></kwd>
<kwd lng="en"><![CDATA[Prostate]]></kwd>
<kwd lng="en"><![CDATA[hyperplasia]]></kwd>
<kwd lng="en"><![CDATA[cancer]]></kwd>
<kwd lng="en"><![CDATA[prostatitis]]></kwd>
<kwd lng="en"><![CDATA[digital rectal examination]]></kwd>
<kwd lng="en"><![CDATA[differential diagnosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McAnnch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Smith y Tanagho. Urología general]]></source>
<year>2013</year>
<edition>18 ed</edition>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Mc Graw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnóstico y tratamiento de la hiperplasia prostática benigna]]></article-title>
<source><![CDATA[GPC]]></source>
<year>2009</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roehrborn]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[McConnell]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiology, physiopathology, epidemiology and natural history of BPH]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Wein]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kavoussi]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Novick]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Partin]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Campbell-Walsh Urology]]></source>
<year>2007</year>
<publisher-loc><![CDATA[St Louis ]]></publisher-loc>
<publisher-name><![CDATA[WB Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Djavan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benign prostatic hyperplasia: current clinical practice]]></article-title>
<source><![CDATA[Prim Care SEP]]></source>
<year>2010</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>583-97</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masumori]]></surname>
<given-names><![CDATA[Naoya]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Journal of Men&#8217;s Health]]></source>
<year>2011</year>
<volume>8</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S19-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Roehrborn]]></surname>
<given-names><![CDATA[C. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Schalken]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Emberton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The progression of benign prostatic hyperplasia]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2011</year>
<volume>39</volume>
<page-range>390-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keen]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diet and benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2011</year>
<volume>54</volume>
<page-range>284-90</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valle Blasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abordaje de la hiperplasia benigna de próstata]]></article-title>
<source><![CDATA[Actuación Atención Primaria-Especializada]]></source>
<year>2003</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>133-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Miner]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Steers]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2011</year>
<volume>186</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>971-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seisen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Drouin]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rouprêt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EMC: Hipertrofia benigna de próstata]]></article-title>
<source><![CDATA[Tratado de Medicina]]></source>
<year>2017</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevención y detección temprana del cáncer de próstata en el primer nivel de atención]]></article-title>
<source><![CDATA[GPC]]></source>
<year>2013</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnóstico y Tratamiento del Cáncer de Próstata en un Segundo y tercer Nivel de Atención]]></article-title>
<source><![CDATA[GPC]]></source>
<year>2010</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerhardt Attard]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate cancer]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>70-82</page-range><publisher-name><![CDATA[Lancet]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Prostate]]></article-title>
<source><![CDATA[American Joint Committee on Cancer (AJCC)]]></source>
<year>2010</year>
<edition>7th ed</edition>
<publisher-loc><![CDATA[Chicago ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-López]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Tacto rectal]]></source>
<year>2019</year>
<publisher-name><![CDATA[Centro de Enseñanza y Certificación de Aptitudes Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seidel]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual Mosby de Exploración física]]></source>
<year>2011</year>
<edition>Séptima edición</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finne]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bangma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hugosson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hakama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Auvinen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2004</year>
<volume>111</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>310-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallejos J]]></surname>
<given-names><![CDATA[Villaronga A]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Mariluis C]]></given-names>
</name>
<name>
<surname><![CDATA[Paganini L]]></surname>
<given-names><![CDATA[González C]]></given-names>
</name>
<name>
<surname><![CDATA[De Luca S]]></surname>
<given-names><![CDATA[Dieguez A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Staging of prostate cancer: An update]]></article-title>
<source><![CDATA[Rev Argent Radiol]]></source>
<year>2013</year>
<volume>77</volume>
<page-range>251-312</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bozeman]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Caldito]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Venable]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Eastham]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2005</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>803-7</page-range><publisher-name><![CDATA[PubMed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zonana-Nacach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa-Torres]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez-Martini]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[López-Manjarrez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate biopsy and relation to prostate-specific antigen in patients diagnosed with benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Revista Mexicana de Urología]]></source>
<year>2014</year>
<volume>74</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>141-5</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rouprêt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Phé]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostatitis y epididimitis]]></article-title>
<source><![CDATA[Tratado de Medicina]]></source>
<year>2010</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krieger]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheah]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Liong]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Riley]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of prostatitis]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2008</year>
<volume>31</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S85-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skerk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schönwald]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krhen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Markovinovic´]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuzmanovic´]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A etiology of chronic prostatitis]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2002</year>
<volume>19</volume>
<page-range>471-4</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<source><![CDATA[Diagnóstico y Tratamiento de la prostatitis aguda]]></source>
<year>2013</year>
<publisher-name><![CDATA[México Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaeffer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weidner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Barbalias]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Botto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Johansen]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Hochreiter]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2003</year>
<volume>2</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brede]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Shoskes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The etiology and management of acute prostatitis]]></article-title>
<source><![CDATA[Nat Rev Urol]]></source>
<year>2011</year>
<volume>8</volume>
<page-range>207-12</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grabe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bjerklund-Johansen]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Botto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naber]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Pickard]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on Urological Infections]]></article-title>
<source><![CDATA[Eur Assoc Urol]]></source>
<year>2013</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>324-33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
